$MAIA

Vitoc Vlad purchased $101K of MAIA

Vitoc Vlad (Chief Executive Officer) purchased 72,700 shares of MAIA Biotechnology, Inc. (MAIA) at $1.39 ($0.10M total) on 2026-06-01.

Original reporting
SEC EDGAR · Vitoc Vlad
Published Jun 2, 2026, 1:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 2, 2026, 1:04 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$MAIA
Bullish
medium confidence
Mentioned
$MAIA
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MAIABullishLow
01

Why it matters

The disclosure updates insider ownership and can influence short-term sentiment, but it does not introduce new clinical, regulatory, or commercial milestones.

02

Market read

Traders may monitor for follow-on insider activity, but the filing alone is unlikely to drive a durable repricing without additional company catalysts.

03

What to watch

No 10b5-1 plan was cited; traders may still discount the signal because the disclosed size/value is modest and lacks accompanying company-specific news.

Relevance 6/10Novelty 6/10Timing: SEC Form 4 filed today (2026-06-02) covering a purchase dated 2026-06-01

Background

This is an SEC insider transaction (Form 4) showing an open-market purchase by MAIA’s CEO/10% owner.

Company-level read

Ticker impact

$MAIABullishMedium confidence
Context

CEO/10% owner Vitoc Vlad bought 72,700 shares of MAIA in an open-market transaction disclosed via SEC Form 4 on 2026-06-02.

Expected impact

Likely limited near-term impact; may modestly support sentiment if market is already watching insider activity.

Evidence & confidence

The filing provides a concrete ownership change and purchase price, but no new operational/clinical/regulatory information or guidance.

Market effects

For biotech, insider buying can slightly improve sentiment, but without trial/data updates it typically won’t reset sector expectations.

None.

None.

Counterpoint

Insider buying may reflect diversification, liquidity planning, or routine compensation/financial management rather than a new positive thesis.

Key entities

  • MAIA Biotechnology, Inc.

    Subject of the insider transaction disclosure; CEO/10% owner purchased shares via open-market purchase.

  • Vitoc Vlad

    CEO, officer/director, and 10% owner who bought 72,700 shares on 2026-06-01.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MAIAMedAI 8/10

MAIA Completes THIO-101 Part C Enrollment; Phase 3 Enrollment Hits 65%

MAIA Biotechnology (MAIA) announced completing enrollment for Part C of its Phase 2 THIO-101 trial and 65% completion for its Phase 3 THIO-104 trial, both evaluating ateganosine in NSCLC. The company reported a 90.5% interim disease control rate for the combination therapy. MAIA aims to enroll 100 patients in THIO-104 by 2026, with an interim analysis planned for 2027. The FDA granted Fast Track designation to ateganosine in July 2025. MAIA shares are up 0.85% at $1.20.

$MAIAMedAI 9/10

MAIA Biotechnology Achieves Patient Enrollment Milestones in Ongoing Phase 2 and Pivotal Phase 3 Clinical Trials in Non-Small Cell Lung Cancer

MAIA Biotechnology (NYSE American: MAIA) reported milestones in its Phase 2 and Phase 3 trials for ateganosine, a telomere-targeting agent for non-small cell lung cancer (NSCLC). Enrollment is complete for Part C of the Phase 2 trial, with 90.5% interim disease control reported. The Phase 3 trial has reached 65% of its 100-patient enrollment target. The FDA granted Fast Track designation to ateganosine in July 2025.